OBJECTIVES:  To conduct a cost-effectiveness assessment of glucose meters (manually coded and autocoded) in diabetes treatment in the Russian Federation. METHODS: Clinical effectiveness assessment was based on the results of modeling of the treatment of patients with diabetes that use manually coded and autocoded blood glucose meters. Cost analysis included assessment of direct and indirect costs that can be associated with manually coded meters (model 1 and model 2) and autocoded meters (model 3). Cost data was based on median prices for medicines, devices, medical services in National healthcare system in the Russian Federation. RESULTS: Annual direct costs per patient in the group of manually coded glucose meters were 1533 euro (model 1) and 1574 euro (model 2), and in the group of autocoded meters were 1557 euro (model 3). Annual total costs per patient in the group of manually coded glucose meters were 2992 euro (model 1) and 2921 euro (model 2), and in the group of autocoded meters were 3034 euro (model 3). Cost-effectiveness ratio for autocoded meters was 1875 euro (model 3) and for manually coded meters was 1954 euro (model 1) and 1982 euro (model 2) per 1 LYG, respectively (discounted at 3%). Budget impact analysis showed that use of autocoded meters (model 3) instead of manually coded (model 1 and model 2) leads to the annually cost savings of 33 euro and 53 euro per patient, respectively (discounted at 3%). CONCLUSIONS: Obtained results approve the use of autocoded blood glucose meters instead of manually coded blood glucose meters to administrate blood glucose level as part of intensive glucose-lowering therapy from a pharmacoeconomic point of view.